BioCryst Pharmaceuticals(FRA) BO1

Market Cap€2.14B

Since IPON/A

5 YearN/A

1 YearN/A

1 MonthN/A

€8.27

-0.98%

-0.08Today

BioCryst Pharmaceuticals Financials at a Glance

Market Cap

€2.14B

Revenue (TTM)

€807.09

Net Income (TTM)

-€327.29

EPS (TTM)

-€1.28

P/E Ratio

-6.56

Dividend

€0.00

Beta (Volatility)

0.08 (Low)

Dividend

€0.00

Beta (Volatility)

0.08 (Low)

Price

€8.27

Volume

Open

€8.27

Price

€8.27

Volume

Open

€8.27

Previous Close

€8.36

Daily Range

€8.27 - €8.27

52-Week Range

€5.18 - €10.19

Estimated Earnings Date

N/A

Dividend

€0.00

Beta (Volatility)

0.08 (Low)

Price

€8.27

Volume

Open

€8.27

Previous Close

€8.36

Daily Range

€8.27 - €8.27

52-Week Range

€5.18 - €10.19

Estimated Earnings Date

N/A

BO1 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The firm focuses on the treatment of rare diseases in which unmet medical needs exist and an enzyme in the biological pathway of the disease. Its programs include BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for marburg virus disease and yellow fever. The company was founded in 1986 and is headquartered in Durham, NC.

Industry

Biotechnology

Sector

Health Care

Employees

435

CEO

Charles K. Gayer, MBA

Website

www.biocryst.com

BO1 Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-15.24%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

€2.14B

Shares Outstanding

255.53M

Volume

Avg. Volume

69.273

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

BioCryst Pharmaceuticals Performance Analysis

BioCryst Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	EUR 257,691,359	93.8%
2023	2023-12-31	EUR 306,546,311	19.0%
2024	2024-12-31	EUR 416,673,617	35.9%
2025	2025-12-31	EUR 775,167,546	86.0%

BioCryst Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	EUR -1.26	45.5%
2023	2023-12-31	EUR -1.09	-13.8%
2024	2024-12-31	EUR -0.40	-63.5%
2025	2025-12-31	EUR 1.07	N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

€187.71

+1.3%

Gross Profit

€183.96

+1.3%

Gross Margin

98.01%

+1.0%

Market Cap

€2.14B

N/A

Market Cap/Employee

€5.11

N/A

Employees

435

N/A

Net Income

€67.42

+15.0%

EBITDA

€85.13

+3.2%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

€867.75

+23.1%

Total Debt

€731.78

+1.2%

Accounts Receivable

€96.87

+1.2%

Inventory

€5.30

+1.2%

Long Term Debt

€690.84

+1.2%

Short Term Debt

€40.94

+1.3%

Return on Assets

-74.60%

+9.3%

Return on Invested Capital

-19.11%

+0.3%

Free Cash Flow

€88.92

+2.4%

Operating Cash Flow

€89.10

+2.4%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

^GSPCS&P 500

^GSPCS&P 500$7,684.24-0.00%

^DJIDJI

^DJIDJI$53,254.61-0.01%

^IXICNASDAQ

^IXICNASDAQ$26,319.55-0.00%

BTCBitcoin

BTCBitcoin$78,890.00-0.00%

SPCXSPCX

SPCXSPCX$142.81+0.01%

AAPLAAPL

AAPLAAPL$315.25-0.01%

AMZNAMZN

AMZNAMZN$258.45-0.03%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

WETOWetour Robotics

WETOWetour Robotics$5.48-0.04%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$71.92+0.00%

INTCIntel

INTCIntel$89.51+0.00%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$44.67+0.02%

NVDANvidia

NVDANvidia$220.78+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.97+0.11%

SOFISoFi Technologies

SOFISoFi Technologies$17.88-0.01%

Questions About BO1

What is the current price of BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals is trading at €8.27 per share.

What is the 52-week range for BioCryst Pharmaceuticals?

Over the past 52 weeks, BioCryst Pharmaceuticals has traded between €5.18 and €10.19.

How much debt does BioCryst Pharmaceuticals have?

As of the most recent reporting period, BioCryst Pharmaceuticals reported total debt of €731.78M.

How much cash does BioCryst Pharmaceuticals have on hand?

BioCryst Pharmaceuticals reported €135.97M in cash and cash equivalents in its most recent financial results.

What is BioCryst Pharmaceuticals’s dividend yield?

BioCryst Pharmaceuticals does not currently have a dividend yield.

BioCryst Pharmaceuticals(FRA) BO1

BioCryst Pharmaceuticals Financials at a Glance

BO1 News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About BioCryst Pharmaceuticals

BO1 Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

BioCryst Pharmaceuticals Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About BO1

What is the current price of BioCryst Pharmaceuticals?

What is the 52-week range for BioCryst Pharmaceuticals?

How much debt does BioCryst Pharmaceuticals have?

How much cash does BioCryst Pharmaceuticals have on hand?

What is BioCryst Pharmaceuticals’s dividend yield?

Premium Investing Services